First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study

2007 Guidelines for the Management of Arterial Hypertension

Giuseppe Mancia, Guy De Backer, Anna F. Dominiczak et al. · Journal of Hypertension · 2007 · 5.8K citations

Medicine, Cardiology, Internal Medicine +17

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Kathy D. Miller, Molin Wang, Julie R. Gralow et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text

Medicine, Oncology, Pharmacology +13

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al. · Journal of Clinical Oncology · 2011 · 1.1K citations

Medicine, Oncology, Pharmacotherapy +15

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David Miles, Arlene Chan, Luc Dirix et al. · Journal of Clinical Oncology · 2010 · 887 citations

Medicine, Oncology, Pharmacology +17

Breast Cancer Among the Oldest Old: Tumor Characteristics, Treatment Choices, and Survival

Mara A. Schonberg, Edward R. Marcantonio, Donglin Li et al. · Journal of Clinical Oncology · 2010 · 427 citations · Full text

Medicine, Geriatric Medicine, Oncology +17